There is continued threat of fungus/Sea lice to hatchery reared Atlantic salmon and in many cases the use of formalin is demonstrating some resistance or the dosage used is having negative impacts o...
RPS Biologiques Inc.
12 enregistrements totalisant 448,829.00 $ CAN, selon les données ouvertes officielles du gouvernement du Canada.
Intégrer ce graphique
Par ministère
| Conseil national de recherches Canada | $448,829 | 12 enregistrements |
Enregistrements
Pilot Study To Assess Efficacy of a Novel DNA and RNAi Vaccine Against ISAV (Infectious Salmon Anemia virus) Infection in Atlantic Salmon (Salmo salar).
The Firm produces Natural Products for fish health company. The Firm is looking to identify co-innovation partners who are experienced in the filed for the development of such products with field tr...
Infections by the parasitic copepod sea lice continue to be a challenge to most Atlantic salmon farming regions of the world, including Atlantic Canada. These host-specific parasites are very pathogen...
The work proposed will take an innovative approach to the control and prevention of sea lice infection using DNA technology to prevent lice from causing infection by blocking their ability to survive...
The work proposed will take an innovative approach to the control and prevention of ISAV infection using DNA/RNAi technology to prevent virus from causing infection by blocking their ability to surviv...
Technical and manufacturing work related to firm's primary business of natural health products for veterinary and human use.
The funding provided from the Innovation Assistance Program is to assist innovative early stage small and medium sized enterprises that are unable to access existing COVID 19 business support
The funding provided by the IAP program is intended to assist innovative small and medium-sized enterprises in the start-up phase that cannot access existing commercial support related to COVID-19.
The funding provided from the Innovation Assistance Program is to assist innovative early stage small and medium size enterprises that are unable to access existing COVID 19 business support.
The project will support development of intellectual property capacity within the firm.